

**DOCKET NO.: ISIS-4502**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: Richard H. Tullis

Confirmation No.: 9155

Application No.: 08/078,768

Group Art Unit: 1634

Filing Date: 06/16/1993

Examiner: N/A

Patent No.: 7,285,537

Issued: 10/23/2007

For: Oligonucleotide Therapeutic Agent and Methods of Making Same

Mail Stop PETITIONS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST TO CORRECT ASSIGNEE UNDER 37 CFR § 3.81 (b)**

A request is made to correct the Assignee under 37 CFR § 3.81(b) for the above-identified application.

The failure to include the correct assignee name on the PTOL-85B form was inadvertent and resulted from a clerical error.

A copy of the Notice of Recordation of Assignment Document reflecting the reel and frame number where the assignment was recorded and reflecting proof of the date the assignment was submitted for recordation is enclosed.

The correct Assignee is "Molecular Biosystems, Inc."

If the Request is granted, Applicant requests that the file be forwarded to the Certificates of Correction Branch for issuance of the Request for Certificate of Correction, filed on January 30, 2012. A courtesy copy of the Request is enclosed.

The request sets forth in § 1.17(i), in the amount of \$130.00, is paid as follows:

Please charge Deposit Account No. 23-3050.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.

Date: March 2, 2012

/Felicity E. Groth/  
Felicity E. Groth  
Registration No. 47,042

Woodcock Washburn LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

FEBRUARY 22, 1983

TO: FULWIDER, PATTON, RIEBER, LEE & UTECHT  
3435 WILSHIRE BLVD., STE. 2400  
LOS ANGELES, CA 90010

RECEIVED

MAR 26 2001

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: 001 KENDREW BIOSYSTEMS, INC.

DOC DATE: 09/28/82

RECORDATION DATE: 01/17/83 NUMBER OF PAGES 003 REEL/FRAME 4079/0445

DIGEST: CHANGE OF NAME - ADDITIONAL PROPERTIES MAY SUBSEQUENTLY INDEXED AGAINST THE ORIGINAL DOCUMENT. THE PAPER REQUESTING SUCH INDEXING MUST ADEQUATELY IDENTIFY ALL SUCH PROPERTIES AND MUST INDICATE THE REEL AND FRAME NUMBER ON WHICH THE ORIGINAL DOCUMENT IS RECORDED.

EFFECTIVE APRIL 2, 1982.

ASSIGNEE: 501 MOLECULAR BIOSYSTEMS, INC.

RECEIVED  
JOAN B. WILSON, PATENT APPEALS  
AND INTERFERENCES  
2001 FEB 14 PM 2:26

SERIAL NUMBER 6-262246 FILING DATE 03/10/81  
PATENT NUMBER ISSUE DATE 00/00/00


TITLE OF INVENTION: METHOD AND APPARATUS FOR GENERATION AND CONTROL OF MAGNETIC FORCE

INVENTOR: 001 KALDIRIM.

SERIAL NUMBER 6-314124 FILING DATE 10/23/81  
PATENT NUMBER ISSUE DATE 00/00/00

TITLE OF INVENTION: OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME

INVENTOR: 001 TULLIS.



State  
of  
California  
OFFICE OF THE SECRETARY OF STATE

I, MARCH FONG EU, Secretary of State of the State of California, hereby certify:

That the annexed transcript was prepared by and in this office from the record on file, of which it purports to be a copy, and that it is full, true and correct.

IN WITNESS WHEREOF, I execute this certificate and affix the Great Seal of the State of California this

SEP 28 1982




RECORDED  
PATENT & TRADEMARK OFFICE  
JAN 17 1983

March Fong Eu

James M. Thompson  
COMMISSIONER OF PATENTS  
AND TRADEMARKS

Secretary of State



Amended  
Statement and Designation by Foreign Corporation

MOLECULAR BIOSYSTEMS, INC. \_\_\_\_\_ a corporation  
organized and existing under the laws of Delaware \_\_\_\_\_  
and which is presently qualified for the  
transaction of intrastate business in the State of California. makes the following statements and/or  
designation:  
1. That the name of the corporation has been changed to that hereinabove set forth and that the name  
relinquished at the time of such change was \_\_\_\_\_  
KENDREW BIOSYSTEMS, INC. \_\_\_\_\_  
2. That the location and address of its principal executive office has been changed and the new location  
and address of its principal executive office is \_\_\_\_\_  
No change \_\_\_\_\_  
(Insert complete address of principal executive office wherever located - Do not use post office box)  
3. That the location and address of its principal office in the State of California has been changed to  
No change \_\_\_\_\_  
(Insert complete address of principal office in California - Do not use post office box)  
4. The address of the individual agent designated for the service of process in the State of California has  
been changed to No change \_\_\_\_\_  
(Do not use post office box)

100-117-1320-10/14/77

543462041338

5. (Use this paragraph if the new process agent designated hereby is a natural person.)

\_\_\_\_\_ a natural person residing in  
the State of California, whose complete  business  residence address is \_\_\_\_\_

(Do not use post office box)

is hereby designated as its new agent upon whom process directed to the corporation may be served within the State of California, in the manner provided by law.

(Note: Either the business address or the residence address must be given. Indicate which by check mark in proper box.)

6. (Use this paragraph if the new process agent designated hereby is a corporation. See instructions.)

The name of its new agent upon whom process directed to the undersigned may be served within the State of California is \_\_\_\_\_

A certificate in compliance with Section 1505 of the California Corporations Code has been filed by said corporate agent.

MOLECULAR BIOSYSTEMS, INC.

(Name of Corporation)

By Kenneth J. Wieder (Title) President  
Kenneth J. Wieder (Title) President

#### INSTRUCTIONS

1. This form is for use by a foreign corporation. Included in the definition "foreign corporation" is a "foreign association" which is defined as "a business association organized as a trust under the laws of a foreign jurisdiction."

2. Use only whichever of the foregoing paragraphs of this Amended Statement are applicable.

3. If this Amended Statement shows a change of corporate name, there must be attached to this Amended Statement a certificate of the public officer having custody of the original corporation documents in the state or place of incorporation to the effect that such change of name was made in accordance with the laws of the state or place of incorporation. In the case of a change of name by a foreign association there must be attached to this amended statement an officers' certificate stating that such change of name was made in accordance with its declaration of trust.

MARCH 23, 1982

TO: FULWIDER, PATTON, RIEBER, LEE & UFECHT  
3435 WILSHIRE BLVD., STE. 2400  
LOS ANGELES, CA 90010

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: 001 TULLIS, RICHARD H.

DOC DATE: 10/29/81

RECORDATION DATE: 10/23/81 NUMBER OF PAGES 003 REEL/FRAME 3941/0775

**DIGEST: ASSIGNMENT OF ASSIGNEE'S INTEREST**

ASSIGNEE: 501 KENDREW BIOSYSTEMS, INC. 11180 ROSELLE ST., STE. A, SAN DIEGO, CA 92121 A CORP. OF DE

SERIAL NUMBER 6-314124 FILING DATE 10/23/81  
PATENT NUMBER ISSUE DATE 00/00/00

TITLE OF INVENTION: OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME

INVENTOR: 001 TULLIS,

A S S I G N M E N T

This Assignment made on *October 9*, 1981, by  
Richard H. Tullis, of La Jolla, California, to Kendrew  
Biosystems, Inc., a Delaware corporation, Assignee, having a  
place of business at 11180 Roselle Street, Suite A, San Diego,  
California 92121.

WHEREAS, Assignor has invented new and useful  
OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME  
for which an application for United States Letters Patent  
has been executed by him this day; and

WHEREAS, Assignor believes himself to be the  
original, first and sole inventor of the invention disclosed  
and claimed in said application for Letters Patent; and

WHEREAS, Assignee desires to acquire by formal,  
recordable assignment the entire right, title and interest in  
and to said invention, said application and any Letters Patent  
that may be granted for said invention in the United States  
and throughout the world;

REEL 394 | FRAME 773

NOW, THEREFORE, in consideration of the sum of Ten  
Dollars (\$10.00) and of other good and valuable consideration,  
the receipt and sufficiency of which are hereby acknowledged,  
Assignor hereby sells, assigns and transfers to Assignee, the  
entire right, title and interest in and to said invention,  
said application and any Letters Patent that may be granted for  
said invention in the United States and throughout the world,  
including the right to file foreign applications directly in

the name of the Assignee.

Further, Assignor agrees that, upon request and without further compensation, but at no expense to Assignor, he and his legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of testimony that may be necessary or desirable for obtaining, sustaining, reissuing or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording or maintaining the title of Assignee, its successors and assigns, to said invention, said application and any Letters Patent granted for said invention in the United States and throughout the world.

Assignor represents and warrants that he has not granted and will not grant to others any rights inconsistent with the rights granted herein.

Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States and of all foreign countries to issue any Letters Patent granted for said invention, whether on said application or on any subsequently filed division, continuation, continuation-in-part or reissue application, to Assignee, its successors and assigns, as the assignee of the entire interest in said invention.

REEL 394 | FRAME 776

IN WITNESS WHEREOF, Assignor has executed this

Assignment on the date first above written.


Assignor

Richard H. Tullis  
Richard H. Tullis

STATE OF CALIFORNIA )  
COUNTY OF San Diego ) ss

On this 9th day of October, in the year of 1981,  
before me personally appeared Richard H. Tullis, known to me to  
be the person whose name is subscribed to the within instrument,  
and acknowledged that he executed the same.

IN WITNESS WHEREOF, I have hereunto set my hand and  
affixed my official seal the day and year in this certificate  
first above written.



Notary Public in and for Said  
110 County and State

REEL 394 | FRAME 777

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:****Tullis****Confirmation No.: 9155****Patent No.: 7,285,537 B1****Issued: October 23, 2007****Application No.: 08/078,768****Filing Date: June 16, 1993****For: Oligonucleotide Therapeutic Agent And Methods Of Making Same**

Commissioner for Patents  
Attn: Certificate of Correction Branch  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR  
APPLICANT'S MISTAKE PURSUANT TO 37 CFR § 1.323**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent. The patent has an error in it that occurred through applicant's fault. Applicant's error occurred in good faith and is of a clerical nature, and is not believed to constitute new matter or require examination.

It is requested that (73) Assignee on the cover page of the patent be corrected to read "Molecular Biosystems, Inc." as is evidenced in the chain of title in parent application 06/314,124 which can be found at:

Reel 4079 Frames 445-447 and Reel 3941 Frames 775-777

Enclosed herewith please find a completed Certificate of Correction form.

- Please charge Deposit Account No. 23-3050 in the amount of \$100.00.
- The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.

**DOCKET NO.: ISIS-4502**

**PATENT**

Date: January 27, 2012

/Felicity E. Groth/  
Felicity E. Groth  
Registration No. 47042

Woodcock Washburn LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,285,537 B1

APPLICATION NO.: 08/078,768

ISSUE DATE : October 23, 2007

INVENTOR(S) : Richard H. Tullis

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page,

Item (73) Assignee:

Delete "ISIS Pharmaceuticals, Inc., Carlsbad, CA (US)" and insert -- Molecular Biosystems, Inc., San Diego, CA (US) --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Woodcock Washburn LLP  
2929 Arch Street  
Philadelphia, PA 19104

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

## Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.